Five patients with hepatic (3), pelvic (1) or spinal (1) hydatid cysts received 0 mg/kg/d albendazole for 1-3 months prior to surgery. Daughter cysts were present in the spinal hydatid and in one patient with hepatic disease. Electron microscope examination of the cyst tissue of the pelvic and the 2 hepatic cysts lacking daughter cysts showed no evidence of germinal layer, and the protoscoleces were dead. The primary cyst of the hepatic hydatid with daughter cysts (I month therapy) was also judged dead but some pieces of the daughter cyst germinal layer appeared normal and had unaffected protoscoleces. The daughter cyst tissue of the spinal hydatid (3 month therapy) appeared normal and the protoscoleces viable. In view of the undetermined viability of human hydatids before chemotherapy, treatment of longer than month is advocated for hepatic cysts, particularly if daughter cysts are present, and longer therapy is indicated for spinal disease.
INTRODUCTION
Although surgery remains the primary treatment for human hydatid disease, there is a growing interest in medical treatment, particularly where resection is contraindicated due to disseminated disease, the condition of the patient or in an adjuvant setting.
Mebendazole was the first drug shown to have an effect albeit inconsistent [2] [3] [4] and more encouraging results have been achieved using albendazole5-7.
Efficacy is generally judged clinically or monitored radiographically to determine cyst regression. When chemotherapy has been followed by surgery, the viability of the protoscoleces within the cyst has been assessed, but less often has the germinal layer of the hydatid been examined histologically, and reports of the ultrastructure of this layer after therapy have been more rare. Verheyen compared human untreated and mebendazole-treated hydatid germinal layer using electron microscopy, and AIDabagh et al. 9 and Gemmell et al. reported the effect of mebendazole on the ultrastructure of sheep hydatids. Morris Figure 1 , whereas the more impoverished germinal layer seen in Figure 2 possesses large mitochondria, laminated residual bodies and sparse glycogen deposits. The ill-defined germinal layer of the 6th tissue piece completely lacked integrity at the EM level. Occasional vesicles were seen in contact with the laminated later (as in Figure 4 ), and lying internal to this, but detached from it, were highly vesiculated fragments of tissue as shown in Figure 3 (Figure 4) . Occasionally, small regions of necrotic tissue, in which myelin figures, lipid droplets and small autophagacytosed glycogen deposits could be seen, remained in contact with the laminated layer ( Figure 5 ). More rarely, profiles as in Figure 6 were observed.
Daughter cyst tissue. At the LM level, no germinal layer was evident in 4 of the 6 pieces examined, the remaining 2 pieces possessing an intact germinal layer with attached brood capsules in which protoscoleces were present. EM examination of the 4 pieces lacking germinal layer at the LM level revealed no tissue remnants whereas the other 2 pieces produced profiles similar to that shown in Figure 7 in which a nucleus, glycogen deposits, lipid deposits, mitochrondria and mucopolysaccharide residual bodies can clearly be seen. Occasional cell masses were observed (not illustrated) and were interpreted as incipient brood capsules. The ultrasections passed through the wall of developed brood capsules, the tissue of which appeared normal and similar to that recorded by Rogan and Richards 7 from control murine and equine tissue. Profiles of protoscoleces were observed and Figure 8 shows part of a protoscolex soma. The tissue is indistinguishable from control material taken from other intermediate hosts16-18. In field trials using sheep 1'!9 aspiration of pulmonary cysts before therapy is possible, but this only reveals the viability or otherwise of the protoscoleces and does not indicate the status of the germinal layer.
DISCUSSION
The vesicular remnants persisting in contact with the laminated layers of the primary cysts are similar to those currently being reported in a study on the long-term effect of albendazole on sheep hydatids 9 and recorded in secondary murine cysts treated in vivo with praziquantel2.
In both sheep and humans, the age of the infection is unknown, and disintegration of the germinal layer through natural death cannot be excluded; in young infections in mouse the collapse and fragmentation of the layer is certainly more likely to have been drug-related.
Daughter cysts were present in patients #4 and 5 and intact germinal layer was observed in both, together with, in patient #5, structurally undamaged protoscoleces. It would appear that therapy of month in patient #5 was insufficient to allow adequate penetration and maintenance of effective drug levels within the daughter cysts to achieve destruction of the germinal layer and protoscoleces. Patient #4 had, however, received albendazole for 3 months prior to surgery. In this case, the apparent inefficacy of the drug might be attributed to the possibly privileged site in which this hydatid occurred. Whilst albendazole does enter the CSF in both man and sheep, the concentrations are considerably less than those present in the serum.
The evidence gained from this study would suggest that albendazole therapy of month is probably not sufficient to kill germinal layer reliably, especially that of daughter cysts, although patients # [1] [2] [3] In the majority of trials of the effectiveness of albendazole against human hydatid disease 10 mg/Kg/day has been the dosage used but the duration and spacing ofcourses of treatment has not been standardised. The efficacy of albendazole has usually been assessed by evidence of cyst regression or by determinations of protoscolex viability following surgical removal of the cyst. It is highly desirable that studies which will provide information on the mode of action of such compounds on hydatid cysts, especially on the germinal layer, are performed if a rational basis for dosages and duration of therapy is to be developed. The approach used in the study reported in this manuscript by Richards and Morris provides some observations ofthis kind but, as the authors state, it is not possible to unequivocally attribute the effects observed to albendazole therapy, especially when such small numbers of patients are involved. Whether the ultrastructural changes found in the non viable cysts are due to albendazole or not, the paper does provide useful descriptions of apparently normal and abnormal hydatid cysts from humans which will be valuable for comparative purposes. In this respect it might have been advantageous to include photomicrographs from the material removed from the other three patients as well or to state that the ultrastructure of those cysts was identical to that ofthe apparently nonviable material from patients 4 and 5.
From the results of this study it does seem clear that one month of treatment at 10mg/Kg/day is probably insufficient and this would appear to be supported by clinical trials in which cyst regression was used as a criterion of success. Even the three month course received by patient No. 4 was inadequate and, though it may be true that the cyst was in a "privaleged site" less accessible to the active drug, it needs to be borne in mind that four months therapy has not always been successful, even in liver. It is for this reason of varied response that more studies are needed, both to determine the effects of albendazole and other chemotherapeutic agents on cysts in different sites and to determine if different hydatid strains respond differently. This paper provides a useful basis for comparison with future investigation.
